A new study published in the British Journal of Psychology has found that individuals who report symptoms of ...

The double-blind, placebo-controlled phase III FOCUS study evaluated solriamfetol versus placebo in adults with ADHD. Patients were ... of the news. The stock price decline could be because ...

Netlify/Decap CMS alternative. Fast, lightweight, Git-based headless CMS. Modern UX, first-class i18n support + 100s of improvements. Open source & free. Made with Svelte.

Investing.com -- Shares of Axsome Therapeutics (NASDAQ:AXSM) fell 5.5% following the announcement of its phase 3 trial results for Solriamfetol in adults with ADHD, which achieved its primary endpoint ...

Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Investing.com -- Shares of Axsome Therapeutics (NASDAQ:AXSM) fell 5.5% following the announcement of its phase 3 trial results for Solriamfetol in adults with ADHD, which achieved its primary ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

TikTok has become the go-to source on ADHD for teens and young adults. But a new study finds that a lot of the information is ...